Evidence map›Paper›PMID 27842566›Full record

ArticleDiagnostic pathology2016

Metachronous serous endometrial intraepithelial carcinoma and serous peritoneal carcinoma: analysis of probable independent lesions.

Mitsuko Furuya, Teiko Sato, Reiko Tanaka, Masafumi Yamamoto, Naho Ruiz Yokota, Etsuko Miyagi

Open access · goldAbstract readCase Reports
In one paragraph

Article in Diagnostic pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Observational
  2. Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 3 institutions in 1 country.

Mitsuko FuruyaDepartment of Molecular Pathology, Yokohama City University Graduate School of Medicine, 3-9 Fukuura, Kanazawa-ku, Yokohama, 236-0004, Japan. mfuruya@yokohama-cu.ac.jp.
Teiko SatoDepartments of Pathology, Keiyu, Hospital, Yokohama, Japan.
Reiko TanakaMedical Mycology Research Center, Chiba University, Chiba, Japan.
Masafumi YamamotoDepartment of Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Naho Ruiz YokotaDepartment of Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Etsuko MiyagiDepartment of Gynecology, Yokohama City University Graduate School of Medicine, Yokohama, Japan.
Yokohama City University · JPChiba University Hospital · JPkeiyu Hospital · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundUterine serous endometrial intraepithelial carcinoma (SEIC) is an immediate precursor of invasive carcinoma. The majority of stage IA SEICs are curable, but those with latent peritoneal metastasis and/or capillary lymphatics invasion may have poor prognoses Careful pathologic staging is thus needed to predict the risk of recurrence and to determine postoperative therapeutic strategies. CASE PRESENTATION: A 71-year-old woman was hospitalized for the treatment of peritoneal carcinoma. She had undergone total hysterectomy and bilateral salpingo-oophorectomy due to SEIC (stage IA) at age 63 years, and had received medical check-ups every year since. Elevated serum CA125 (184 U/mL) was detected for the first time 8 years after surgery. A thorough workup revealed no potential primary lesion other than that in the peritoneum. Tumor reduction surgery was performed. Histologic analysis of the peritoneal lesion was high-grade serous carcinoma. The peritoneal carcinoma was diffusely immunostained for p53; thus, possible recurrence of SEIC was suspected. Tumor DNAs were microdissected from the uterine and peritoneal lesions and p53 mutation analysis was done. SEIC and peritoneal carcinomas had distinct p53 mutations that were mutually exclusive.

conclusionsThe present case raised a concern about the difficulty of histologic staging for SEICs. Although SEICs confined to the uterine endometrium in most cases predict a good prognosis, microscopic metastasis to the peritoneum may not be detectable at hysterectomy. If secondary malignancies of a serous phenotype develop years later, comprehensive reexamination of SEIC is mandated, with the help of DNA analysis.

Indexed as

Adenocarcinoma in SituAgedBiomarkers, TumorCystadenocarcinoma, SerousDNA Mutational AnalysisEndometrial NeoplasmsFemaleHumansImmunohistochemistryMutationNeoplasms, Multiple PrimaryPeritoneal NeoplasmsTumor Suppressor Protein p53Biomarkers, TumorTP53 protein, humanTumor Suppressor Protein p53Case reportImmunohistochemistryp53Peritoneal serous carcinomaSomatic mutationSuperficial uterine serous carcinoma (SEIC)

Identifiers

PMID27842566
PMCPMC5108080
OpenAlexW2556160467

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.